Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial
Titel:
Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial
Auteur:
Lebbé, Céleste Italiano, Antoine Houédé, Nadine Awada, Ahmad Aftimos, Philippe Lesimple, Thierry Dinulescu, Monica Schellens, Jan H. M. Leijen, Suzanne Rottey, Sylvie Kruse, Vibeke Kefford, Richard Raymond, Eric Faivre, Sandrine Pages, Celine Gomez-Roca, Carlos Schueler, Armin Goodstal, Samantha Massimini, Giorgio Delord, Jean-Pierre